Approved for use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCO
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO				Complete if Known		
	INFORMATION	DISCLOSURE	Application Number	10/519,715		
	STATEMENT B	Y APPLICANT	Filing Date	11/12/2004		
	Date Submitted: E	shruur 13 2009	First Named Inventor	Kristin WANNERBERGER		
Date Submitted: February 13, 2009 (use as many sheets as necessary)			Art Unit	1615		
			Examiner Name	Jeffrey T. Palenik		
Sheet	1	of 1	Attorney Docket Number	052209-0132		

U.S. PATENT DOCUMENTS					
Examine r Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Se comme					

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (# known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	anorm)			rigues /ippear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (yf known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
						T

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T'	
	A1	LACZI, F. et al., "Effects of vasopressin analogues (DDAVP, DVDAVP) in the form of sublingual tablets in central diabetes insipletus", International Journal of Clinical Pharmacology, Therapy and Toxicology, Vol. 18, No. 12, pp.63-68 (1980).		
			1	

Examiner Signature	Date Considered	

*EXAMINE: Initial ir reference considered, whether or not citation is in conformance with MEPE 900. Draw the through citation if not in conformance and not considered include copy of the form white communication applicant. 1 Applicant is unique citation designation number (opiginal), 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MEPE 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3), 4 For Japanese patent documents, the indication of the year of the represent must precede the search number of the patent of occument by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark there if English language.

Interesting in a statistical or differentiation is equived by 37 CFF I 97 and 198. The information is required to obtain or retain a benefit by the public which is to its part by the Time collection of unformation is required by 37 LFC III 32 and 37 CFF I 1.1 ET has 07 CFF I 1.1 ET has